Compare IIPR & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIPR | NUVB |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2016 | 2020 |
| Metric | IIPR | NUVB |
|---|---|---|
| Price | $56.20 | $5.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $45.00 | $11.38 |
| AVG Volume (30 Days) | 216.0K | ★ 4.6M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 14.28% | N/A |
| EPS Growth | N/A | ★ 71.56 |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $265,955,000.00 | $62,902,000.00 |
| Revenue This Year | $2.69 | $203.82 |
| Revenue Next Year | $3.80 | $58.18 |
| P/E Ratio | $23.54 | ★ N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $44.58 | $3.00 |
| 52 Week High | $65.38 | $9.75 |
| Indicator | IIPR | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 37.55 |
| Support Level | $56.04 | $5.28 |
| Resistance Level | $57.60 | $6.25 |
| Average True Range (ATR) | 1.05 | 0.28 |
| MACD | 0.11 | -0.12 |
| Stochastic Oscillator | 34.13 | 8.99 |
Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.